$4.5199
0.0399[0.89%]
At close: Apr 26
$4.5199
0[0.00%]
After Hours: 5:46PM EDT
Vanda Pharma
(NASDAQ:VNDA)Latest News for Vanda Pharma Stock (NASDAQ:VNDA)
Vanda Pharma Stock (NASDAQ: VNDA)
Categories: All
Thursday, April 25, 2024
Monday, April 22, 2024
- US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, HetliozVandana Singh - 4 days ago
- Vanda Pharmaceuticals shares are trading lower after the US Supreme Court reportedly declined to hear the company's case regarding the invalidation of patents for Hetlioz.Benzinga Newsdesk - 4 days ago
- 'The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals' Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva And Apotex' - Yahoo FinanceBenzinga Newsdesk - 4 days ago
Friday, April 19, 2024
Wednesday, April 17, 2024
- Crude Oil Dips 3%; U.S. Bancorp Profit Tops ViewsAvi Kapoor - Apr 17, 2024, 2:34PM
- Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Apr 17, 2024, 1:36PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Apr 17, 2024, 12:31PM
- Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/ShareVandana Singh - Apr 17, 2024, 12:29PM
- Vanda Pharmaceuticals Adopts 1-Year Term Limited Duration Stockholder Rights Plan To Protect Stockholder Interests And Maximize Value For All Stockholders, Effective ImmediatelyBenzinga Newsdesk - Apr 17, 2024, 10:26AM
- Vanda Pharmaceuticals Confirms Rejection Of Unsolicited Takeover Proposals From Future Pak; Says "Board Determined Unsolicited Takeover Proposals Significantly Undervalue The Company"Benzinga Newsdesk - Apr 17, 2024, 9:05AM
- Market-Moving News for April 17thBenzinga Newsdesk - Apr 17, 2024, 8:33AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Apr 17, 2024, 8:08AM
- Vanda Pharmaceuticals shares are trading higher after the company announced that it submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals and confirmed that its most recent proposal to acquire Vanda remains open for Vanda and its Board of Directors to consider.Benzinga Newsdesk - Apr 17, 2024, 7:42AM
- Future Pak Announced That It Has Submitted Three Proposals Since February To Acquire Vanda Pharmaceuticals And Confirms That Its Most Recent Proposal Of $7.25-$7.75 Per Share Remains Open For Vanda And Its Board Of Directors To ConsiderBenzinga Newsdesk - Apr 17, 2024, 6:31AM
Thursday, April 04, 2024
Wednesday, April 03, 2024
- Nasdaq Gains 75 Points; Acuity Brands Posts Upbeat EarningsAvi Kapoor - Apr 3, 2024, 2:30PM
- Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Apr 3, 2024, 1:56PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Apr 3, 2024, 12:31PM
- Crude Oil Moves Higher; ISM Services PMI Falls In MarchAvi Kapoor - Apr 3, 2024, 12:01PM
- Why Is Vanda Pharmaceuticals Stock Trading Higher Today?Vandana Singh - Apr 3, 2024, 8:48AM
- Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Apr 3, 2024, 8:10AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Apr 3, 2024, 8:09AM
- Vanda Pharmaceuticals shares are trading higher after the company's Fanapt received FDA approval for the acute treatment of bipolar I disorder.Benzinga Newsdesk - Apr 3, 2024, 7:05AM
- Reported Earlier, Vanda Pharmaceuticals' Fanapt® Received U.S. FDA Approval For The Acute Treatment Of Bipolar I DisorderBenzinga Newsdesk - Apr 3, 2024, 2:58AM
Wednesday, March 06, 2024
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Mar 6, 2024, 8:07AM
- Vanda Pharmaceuticals shares are trading lower after the company revealed the receipt of a FDA complete response letter for HETLIOZ (tasimelteon) for insomnia treatment.Benzinga Newsdesk - Mar 6, 2024, 7:20AM
- Vanda Pharmaceuticals Receives Complete Response Letter From FDA As Part Of Ongoing Review Of sNDA For HETLIOZ (Tasimelteon) In Insomnia Treatment Characterized By Difficulties With Sleep InitiationBenzinga Newsdesk - Mar 6, 2024, 7:03AM
Wednesday, February 07, 2024
Tuesday, February 06, 2024
Monday, February 05, 2024
Wednesday, January 31, 2024
Tuesday, January 30, 2024
Monday, January 29, 2024
Friday, January 26, 2024
Thursday, January 25, 2024
- Vanda Pharmaceuticals Announces The U.S. Patent And Trademark Office Issued A Notice Of Allowance For PONVORY #17/962,968, Covering Methods For Reducing Clinical Management Events Before Or During The Treatment Of MS And Methods For Reinitiating Treatment After Missed DosesBenzinga Newsdesk - Jan 25, 2024, 10:17PM
- Vanda Pharmaceuticals Announces Publication Of An Article On "The Efficacy Of Tradipitant In Patients With Diabetic And Idiopathic Gastroparesis In Phase III Randomized Placebo-Controlled Clinical Trial" In The Clinical Gastroenterology And HepatologyBenzinga Newsdesk - Jan 25, 2024, 1:12PM
Tuesday, January 23, 2024
Friday, January 19, 2024
Friday, January 12, 2024
Thursday, December 07, 2023
- Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's CompanyVandana Singh - Dec 7, 2023, 12:32PM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Dec 7, 2023, 8:07AM
- Vanda Pharmaceuticals Inc. Shares To Resume Trade At 7:30 a.m. ETBenzinga Newsdesk - Dec 7, 2023, 7:11AM
- Vanda Pharmaceuticals Has Acquired U.S. And Canadian Rights To Ponvory (Ponesimod) From Actelion Pharmaceuticals, A Johnson & Johnson Company, Approved For Relapsing Forms Of Multiple Sclerosis, Vanda Paid $100MBenzinga Newsdesk - Dec 7, 2023, 7:06AM